Please assess the completion status of the following clinical trial:

Trial Title: A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for inclusion into this study, each patient must fulfil the following inclusion criteria ≤ 28 days prior to the anticipated surgery date:~1. Malignant glioma (WHO grade III or IV) who have undergone conventional treatment, including surgery (gross total resection or unintentional partial resection with residual tumour) or biopsy (with residual tumour), and/or radiation therapy, and/or chemotherapy, and/or Temozolomide and have progressive and/or multiple recurrent GBM. Preoperative assessment by clinical presentation and CT/MRI appearance of the lesion will identify suitable candidates.~2. Age 18-75 years.~3. Karnofsky \>70 (see APPENDIX C: EXAMPLE OF PERFORMANCE STATUS: KARNOFSKY SCALE).~4. Stable dose of corticosteroids no longer than 4 weeks prior to enrolment.~5. Females of childbearing potential must have a negative serum or urine pregnancy test.~   Females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential.~6. Females of childbearing potential and males who have not undergone surgical sterilization must agree to practice a form of effective contraception prior to entry into the study and for 1 month after the end of infusion.~   Effective contraception:~   If female, is non-lactating, has a negative urine pregnancy test result, and does not plan on becoming pregnant during the study, or not of childbearing potential (hysterectomy or tubal ligation at least 6 months prior to entry to the study or post-menopausal for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice or be willing to continue to practice acceptable birth control from screening and until 1 month after the study medication has been discontinued.~   Acceptable birth control includes:~  1. Combined (oestrogen and progestogen containing) hormonal contraception;~  2. Associated with inhibition of ovulation; oral OR intravaginal OR transdermal;~  3. Progestogen-only hormonal contraception associated with inhibition of ovulation: oral OR injectable OR implantable;~  4. Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action;~  5. Intrauterine device (IUD);~  6. Intrauterine hormone-releasing system (IUS);~  7. Bilateral tubal occlusion;~  8. Vasectomised partner;~  9. Sexual abstinence;~  10. Male or female condom with or without spermicide;~  11. Cap, diaphragm or sponge with spermicide. Complies with The Heads of Medicines Agencies (HMA) Recommendations Related to Contraception and Pregnancy Testing in Clinical Trials (Sept 2014).~   The definition of effective contraception will be based on the judgment of the investigator.~7. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~To be eligible for inclusion into this study, each patient must violate none of the following exclusion criteria ≤ 28 days prior to the anticipated surgery date:~1. Patients who had chemotherapy, radiotherapy or other anti-neoplastic therapy (within 4 weeks or 5x half-life whichever is shorter) prior to study treatment or those who have not recovered to Grade ≤1 or returned to baseline from any acute treatment-related toxicities of the previous therapy except for alopecia and Grade 2 neuropathy.~2. Patients who are receiving any other investigational agents.~3. Life expectancy \<3 months~4. Haematological dysfunction defined as:~   * White blood cell (WBC) count \<3.0 x 109/L;~  * Absolute neutrophil count \<1.5 x 109/L;~  * Haemoglobin level \<10.0 g/dL;~  * Platelet count \<100 x 109/L.~5. Liver dysfunction defined as:~   * Aspartate transaminase (AST) \>2.5 x the upper limit of normal (ULN) for age and gender;~  * Alanine transaminase (ALT) \>2.5 x the ULN for age and gender;~  * Bilirubin \>1.5 x the ULN for age and gender.~6. Renal dysfunction defined as:~   - Creatinine clearance \<60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal for age and gender.~7. Serology indicating active infection with Hepatitis B or C, or HIV.~8. Significant co-morbidity, including coagulation disorders.~9. Pregnancy or unwillingness to practice reliable birth control.~10. Presence of another active malignancy less than 2 years previously (exception: non-melanoma skin cancer).~11. Multifocal, bilateral~12. Midline shift more than 5 mm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- hrBMP4 (Type: EXPERIMENTAL): Intra-tumour and interstitial convection enhanced delivery (CED) as a continuous infusion via intracranial catheters of hrBMP4 solution and gadolinium

Based on this trial design, predict the completion outcome and termination type (if applicable).